Telix Pharmaceuticals Limited
TLX.AXHealthcareASXBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeTelix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. At a $4.41B market cap, Telix Pharmaceuticals Limited ranks as a mid-cap company within healthcare. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Market Cap
$4.41B
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
102.98
EPS (TTM)
$-0.03
EPS (Fwd)
$0.13
ROE
-1.9%
ROA
1.1%
Cash
$141.9M
Total Debt
$467.1M
Free CF
-$36.7M
52W Change
-50.0%
Annual Financials
Cash vs Debt
The company holds $141.9M in cash, though total debt stands at $467.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$36.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -1.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $108.9M (2022) to $803.8M (2025), reflecting a 638% increase over the period.
With a beta below 0.7, Telix Pharmaceuticals Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Telix Pharmaceuticals Limited's trajectory.